HALO - Halozyme Therapeutics, Inc.
18.00 0.00 (0.01%)
After hours: 4:46PM EDT
| Previous Close | 17.51 |
| Open | 17.45 |
| Bid | 17.00 x 4000 |
| Ask | 18.90 x 800 |
| Day's Range | 17.34 - 18.02 |
| 52 Week Range | 11.41 - 21.48 |
| Volume | 532,041 |
| Avg. Volume | 776,514 |
| Market Cap | 2.577B |
| Beta | 3.27 |
| PE Ratio (TTM) | 37.74 |
| EPS (TTM) | 0.48 |
| Earnings Date | Aug 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.56 |
- PR Newswire•9 days ago
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
SAN DIEGO , July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application from Genentech, ...
- PR Newswire•14 days ago
Halozyme To Host Second Quarter 2018 Financial Results Conference Call
SAN DIEGO , July 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
Markit•17 days agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Index (PMI) data, output in the Healthcare sector is rising.
Markit•22 days agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Short interest is moderate for HALO with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Over the last month, growth of ETFs holding HALO is favorable, with net inflows of $5.50 billion.
- Simply Wall St.•23 days ago
How Did Halozyme Therapeutics Inc’s (NASDAQ:HALO) 25.81% ROE Fare Against The Industry?
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between Halozyme Therapeutics Inc (NASDAQ:HALO)’s returnRead More...
- ACCESSWIRE•28 days ago
Free Technical Research on ImmunoGen and Three More Biotech Equities
On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu ...
- PR Newswire•last month
Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
SAN DIEGO, June 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced Dr. Helen Torley, president and chief executive officer, was awarded the honor of Entrepreneur Of The Year® 2018 San Diego in the category of Operational Excellence by a panel of independent judges. The EY Entrepreneur Of The Year program recognizes the endeavors of exceptional entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. "Under Helen's leadership, Halozyme has not only made significant progress growing the ENHANZE technology franchise and studying the potential for our investigational oncology drug, but also in strengthening our culture and commitment to excellence.
Markit•last monthSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•2 months ago
Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer
-- Janssen Presenting Five Clinical Studies of subcutaneous daratumumab with Halozyme ENHANZE Technology-- SAN DIEGO , June 1, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology ...
- PR Newswire•2 months ago
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
SAN DIEGO , May 29, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor ...
- Investor's Business Daily•2 months ago
Halozyme Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Halozyme Therapeutics (HALO) earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. [ibd-display-video id=3105496 width=50 float=left autostart=true] When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Major U.S. markets closed up on Monday, with the Dow Jones posting its 8th consecutive daily gain, as trade tensions between U.S. and China eased. The Dow Jones ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Halozyme Therapeutics Inc Earnings Call
- Associated Press•2 months ago
Halozyme Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- PR Newswire•2 months ago
Halozyme Reports First Quarter 2018 Results
-- Revenue of $30.9 Million Includes a 50 Percent Increase in Royalty Revenue on a Reported Basis -- -- Eight ENHANZE®-Partnered Products Expected in Clinical Studies in 2018, Two More than Forecasted ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•3 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•3 months ago
Halozyme To Host First Quarter 2018 Financial Results Conference Call
SAN DIEGO , April 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
- Business Wire•4 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Halozyme Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
- PR Newswire•4 months ago
Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
SAN DIEGO, March 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the nomination of Jean-Pierre Bizzari, M.D. and James M. Daly as Class II directors for reelection at the Company's 2018 stockholder meeting. Following communication by Randal J. Kirk of his unavailability for further service due to growing commitments outside Halozyme, it has been agreed that Mr. Kirk will not be nominated for reelection to the board of directors. Mr. Kirk joined the board of directors nearly 11 years ago at a formative time for the company and remains Halozyme's largest shareholder.
- PR Newswire•4 months ago
Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
SAN DIEGO , March 14, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present nonclinical data from ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of HALO earnings conference call or presentation 20-Feb-18 9:30pm GMT
Q4 2017 Halozyme Therapeutics Inc Earnings Call
- PR Newswire•5 months ago
Halozyme Therapeutics To Present At Upcoming Healthcare Conference
SAN DIEGO , Feb. 27, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the Cowen & Company ...
Markit•5 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
